These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20532049)

  • 41. Characterization of a three-drug nonlinear mixture response model.
    Brun YF; Greco WR
    Front Biosci (Schol Ed); 2010 Jan; 2(2):454-67. PubMed ID: 20036961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of synergism in drug combinations and reference models for future orientations in oncology.
    Duarte D; Vale N
    Curr Res Pharmacol Drug Discov; 2022; 3():100110. PubMed ID: 35620200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decimal assay for additivity of drugs permits delineation of synergy and antagonism.
    Sanders CC; Sanders WE; Moland ES
    Antimicrob Agents Chemother; 1993 Feb; 37(2):260-4. PubMed ID: 8452356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
    Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG
    Mol Cancer Ther; 2014 Jul; 13(7):1964-76. PubMed ID: 24755197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility.
    Hendrickx JF; Eger EI; Sonner JM; Shafer SL
    Anesth Analg; 2008 Aug; 107(2):494-506. PubMed ID: 18633028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Applying Emax model and bivariate thin plate splines to assess drug interactions.
    Kong M; Lee JJ
    Front Biosci (Elite Ed); 2010 Jan; 2(1):279-92. PubMed ID: 20036878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.
    Zhao L; Au JL; Wientjes MG
    Curr Cancer Drug Targets; 2017; 17(8):735-755. PubMed ID: 28359247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Co-administration of morphine and gabapentin leads to dose dependent synergistic effects in a rat model of postoperative pain.
    Papathanasiou T; Juul RV; Heegaard AM; Kreilgaard M; Lund TM
    Eur J Pharm Sci; 2016 Jan; 82():97-105. PubMed ID: 26610393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Revisiting the isobole and related quantitative methods for assessing drug synergism.
    Tallarida RJ
    J Pharmacol Exp Ther; 2012 Jul; 342(1):2-8. PubMed ID: 22511201
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models.
    Wiśniowska B; Lisowski B; Kulig M; Polak S
    J Appl Toxicol; 2018 Apr; 38(4):450-458. PubMed ID: 29143966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.
    Van der Borght K; Tourny A; Bagdziunas R; Thas O; Nazarov M; Turner H; Verbist B; Ceulemans H
    Sci Rep; 2017 Dec; 7(1):17935. PubMed ID: 29263342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New models for the time dependent toxicity of individual and combined toxicants.
    Lambert RJW; Dawson DA
    Toxicol Res (Camb); 2019 Jul; 8(4):509-521. PubMed ID: 31367334
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additivity of inhibitory effects in multidrug combinations.
    Russ D; Kishony R
    Nat Microbiol; 2018 Dec; 3(12):1339-1345. PubMed ID: 30323252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Charting the Fragmented Landscape of Drug Synergy.
    Meyer CT; Wooten DJ; Lopez CF; Quaranta V
    Trends Pharmacol Sci; 2020 Apr; 41(4):266-280. PubMed ID: 32113653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.
    Vlot AHC; Aniceto N; Menden MP; Ulrich-Merzenich G; Bender A
    Drug Discov Today; 2019 Dec; 24(12):2286-2298. PubMed ID: 31518641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation.
    Wiśniowska B; Polak S
    Curr Pharmacol Rep; 2016; 2(6):339-344. PubMed ID: 27917367
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies.
    Whitehead A; Su TL; Thygesen H; Sperrin M; Harbron C
    Pharm Stat; 2013; 12(5):300-8. PubMed ID: 23907796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study.
    Thorlund K; Mills E
    Clin Epidemiol; 2012; 4():75-85. PubMed ID: 22570567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergism between rocuronium and cisatracurium: comparison of the Minto and Greco interaction models.
    Jeon S; Kwon JY; Kim HK; Kim TK
    Korean J Anesthesiol; 2016 Aug; 69(4):341-9. PubMed ID: 27482310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
    Levasseur LM; Greco WR; Rustum YM; Slocum HK
    Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.